Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 58.08

+0.9%

3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Icebrg who wrote (9616)	12/2/2003 6:31:08 PM
From: Biomaven	Read Replies (2) of 52153

Pixantrone which to me looks like a very promising late-stage drug candidate I absolutely agree on this - it looks like a gem to me. The question is whether there will be bad news on Xyotax before good news on Pix. Unfortunately with such a big short position anything resembling bad news gets seriously amplified (although I note that TSC no longer seems to be an outlet for shorters' "amplifications."). Trisenox for myelodysplastic syndromes (MDS) is something of a wild card. There are some abstracts on this at ASH that I haven't looked at yet. I own a little CTIC bought a while back at lower levels. Not sure if I'm brave enough to add more in the face of the shorts. Peter

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next